The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.

April serves as Testicular Cancer Awareness Month, which is the most common type of cancer in men aged between 15 and 44 ...

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

Use of NeuroSAFE during prostatectomy nearly doubled the number of patients who had no or mild erectile dysfunction ...

KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic ...

Testicular cancer is rare but highly curable, especially with early detection; treatment varies by stage, and follow-up care ...

Lynch syndrome demands proactive health management, including regular screenings like colonoscopies and endoscopies, to ...

It isn’t easy having cancer. But like gardening in a harsh climate, survival and growth come from strategies, adaptation, and ...

The U.S. Food and Drug Administration (FDA) has granted full approval to Vitrakvi (larotrectinib) for the treatment of adult ...

The U.S. Food and Drug Administration has approved Jobevne (bevacizumab-nwgd), a biosimilar to Avastin (bevacizumab) for ...

CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the ...

The FDA has approved Opdivo with Yervoy for the first-line treatment of adults with unresectable or metastatic hepatocellular ...